IMIPENEM AND CILASTATIN (imipenem and cilastatin sodium) by Merck & Co. is (i. Approved for the following serious infections caused by designated susceptible bacteria: lower respiratory tract infections, lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species and 37 more indications. First approved in 2011.
Drug data last refreshed 18h ago
(I.V.) is a combination of imipenem and cilastatin. Imipenem is a penem antibacterial drug [see Microbiology ( )] . Cilastatin is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.
Worked on IMIPENEM AND CILASTATIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects